Skip to main content

Table 3 Results of uni- and multivariate analyses for biochemical progression-free survival (bRFS)

From: Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy

  Univariate analysis Multivariable analysis
p value p value OR, (95% CI)
Initial T stage (≤T2 vs ≥ T3) 0.02 0.50 1.43 (0.50–4.11)
Initial N stage (N0 vs N1) 0.07 0.07 3.75 (0.89–15.81)
Initial PSA level in ng/ml (≤20 vs > 20) 0.36   
PSA nadir after RP (≤0.07 ng/mL vs > 0,07 ng/mL) 0.04 0.14 2.24 (0.78–6.45)
Number of removed LN at RP (≤15 vs > 15) 0.32   
Initial Risk Group (intermediate+high risk vs. very high risk) 0.15   
PSA doubling time (≤6 months, > 6 months) 0.46   
Radiotherapy type (CF-RT vs. SBRT) 0.11   
No. of irradiated metastases (1 vs > 1) 0.37   
Type of metastases (lymph node vs bone) 0.18   
Concurrent ADT (yes vs no) 0.03 0.01 7.86 (1.51–40.79)
RT-Dose (≤50 Gy vs > 50 Gy) 0.74   
  1. ADT androgen deprivation therapy, CF-RT conventionally fractionated radiotherapy type, dt doubling time, Gy Gray, LN lymph nodes, PSA prostate-specific antigen, RP radical prostatectomy, sRT salvage radiotherapy, SBRT stereotactic body radiation therapy, SIB simultaneous integrated boost